SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is trending due to mixed market reactions following its Q4 earnings beat, as the stock experiences a significant dip despite exceeding revenue and EPS estimates. Community discussion centers on concerns over decelerating subscriber growth and conservative 2026 guidance, alongside the ongoing drama and shareholder sentiment surrounding the proposed Warner Bros. acquisition and its impact on buybacks and future debt.

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

Alpha Tau Medical is a trending topic as anticipation grows for its potential PMDA approval in Japan and its presentation at the J.P. Morgan Healthcare Conference, driving significant community discussion. Investors are actively highlighting the company's innovative Alpha DaRT technology and recent strong clinical data in pancreatic cancer, signaling a potential shift towards increased institutional interest in this transformative oncology player.

SPDR Gold Trust - SPDR Gold Shares

SPDR Gold Shares ETF

GLD is trending as escalating geopolitical tensions, particularly surrounding potential US tariffs on European countries over Greenland, drive a significant 'risk-off' rotation in the markets. The community is actively discussing gold as a premier safe-haven asset, anticipating continued strong upside as investors seek protection against market instability and potential fiat currency debasement. This robust demand is pushing the metal to new highs amidst broader concerns over the US dollar and global economic conditions.

Hycroft Mining Holding Corp. engages in the exploration, mining, and development of gold and silver properties. The company was founded on August 28, 2017 and is headquartered in Winnemucca, NV.

Hycroft Mining Holding Corporation - Ordinary Shares - Class A

Hycroft Mining Holding Corp

Hycroft Mining is trending due to recent reports of exceptionally high-grade silver drill results from its Nevada project and a broader surge in precious metals prices. The community is actively discussing continued accumulation by billionaire investor Eric Sprott and the potential for a significant short squeeze, while also noting recent commentary from CEO Diane Garrett regarding the company's capital position. Despite enthusiasm for its vast resources, some caution against its current lack of commercial production amid a rapidly rising valuation.

Ondas Holdings, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Inc.

Ondas Holdings Inc

Ondas Holdings is trending following an investor day that revealed significantly raised revenue guidance and prompted numerous analyst price target upgrades, signaling strong confidence in its future trajectory. The community is actively discussing the company's robust position in autonomous systems, anticipating a substantial run fueled by potential defense contracts and strategic acquisitions. Despite broader market volatility, investors view recent dips as buying opportunities, reinforcing the long-term growth outlook in critical defense and communication infrastructure.

C3.ai, Inc. engages in the provision of enterprise artificial intelligence software for digital transformation. It delivers the C3 AI suite for developing, deploying, and operating large-scale AI, predictive analytics, and Internet of Things applications in addition to a portfolio of turn-key AI applications. It operates through the following geographical segments: North America, Europe, The Middle East, and Africa, Asia Pacific, and Rest of World. The company was founded by Thomas M. Siebel, Patricia A. House and Stephen Maurice Ward, Jr. on January 8, 2009 and is headquartered in Redwood City, CA.

C3.ai Inc - Ordinary Shares - Class A

C3.ai Inc

C3.ai is trending due to recent significant government contract wins, notably with the U.S. Department of Health and Human Services and the U.S. Army, signaling increasing adoption of its enterprise AI solutions within the public sector. The community is actively debating whether these new contracts, combined with its high short interest and new leadership, position the company for a major turnaround despite past financial concerns and ongoing skepticism about its long-term growth trajectory.

ProShares Trust - ProShares UltraShort Bloomberg Natural Gas -2x Shares

ProShares UltraShort Bloomberg Natural Gas

KOLD is experiencing extreme volatility as natural gas prices surge dramatically, driven by recent colder weather forecasts and a significant short squeeze in the underlying commodity. This has led to a substantial decline in KOLD, with traders actively debating buying the dip amidst widespread discussion of the natural gas market's 'widowmaker' reputation. The community remains focused on weather pattern shifts and the sustainability of this rapid price movement, highlighting the inherent high risk of leveraged natural gas ETFs.

Anteris Technologies Global Corp. is a structural heart company, which engages in the development and commercialization of medical devices for heart diseases. It operates through the following geographical segments: United States, Germany, Australia, Switzerland, and Sweden. The company was founded in 1999 and is headquartered in Eagan, MN.

Anteris Technologies Global Corp.

Anteris Technologies Global

Anteris Technologies (AVR) is currently trending following a significant strategic investment of up to $90 million from Medtronic and a concurrent public offering, which has sparked varied community reactions. While the Medtronic backing is widely viewed as a strong industry endorsement for its innovative DurAVR technology and potential for serious growth, concerns about substantial share dilution from the offering are also actively debated among investors. This comes as the company advances its global pivotal trial for the DurAVR heart valve, targeting the multi-billion-dollar TAVR market.

Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals is trending following positive Phase 1 clinical trial data for its eczema drug, soquelitinib, which showed significant efficacy and safety, particularly in treatment-resistant patients. This promising development has fueled speculation about its blockbuster potential and future partnerships, even as the company's recent public offering sparks debate among investors regarding potential dilution versus funding for accelerated pipeline progression. The community is actively discussing the drug's strong profile and the ongoing battle between bulls and bears as the stock experiences substantial volatility.

TE Connectivity Plc is a company that engages in the provision of connectivity and sensor solutions for the purpose of distribution of power, signal, and data. It operates under the following segments: Transportation Solutions, Industrial Solutions, and Communications Solutions. The Transportation Solutions segment include terminals and connector systems and components, sensors, relays, antennas, and application tooling. The Industrial Solutions segment include terminals and connector systems and components, interventional medical components, relays, heat shrink tubing, and wire and cable. The Communications Solutions segment include terminals and connector systems and components, antennas, and heat shrink tubing. The company was founded in 2007 and is headquartered in Galway, Ireland.

TE Connectivity plc - Registered Shares

TE Connectivity Ltd - Registered Shares

TE Connectivity is trending following its robust fiscal Q1 earnings, which significantly exceeded expectations for both revenue and EPS, coupled with an optimistic outlook for the coming quarter. The community is highlighting the company's record orders and strong execution in high-growth areas like AI, next-gen vehicles, and energy infrastructure, leading to a largely bullish sentiment among analysts and investors.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Ocular Therapeutix had reportedly rejected Sanofi’s initial takeover bid in September.</li><li>If the acquisition goes through, it would bolster Sanofi’s footprint in ophthalmology.</li><li>Sanofi recently acquired Dynavax to boost its vaccine portfolio.</li></ul>Ocular Therapeutix (OCUL) was back on retail’s radar, with the stock surging 13% in premarket trading on Thursday, after reports emerged that French pharmaceutical giant Sanofi (SNY) is preparing an offer to acquire the American biopharmaceutical firm.According to French publication La Lettre, the renewed interest comes after Ocular Therapeutix rejected Sanofi’s initial takeover bid in September, when the group offered $16 per share, a substantial premium to Ocular’s then-trading price of about $10.50.<a href="https://stocktwits.com/symbol/OCUL">OCUL shares</a> have been on a downtrend lately, declining in 11 of the last 13 sessions. <a href="https://stocktwits.com/symbol/SNY">SNY stock</a> was down 0.4% in pre-open trade.<h2 class="st-heading-2">Acquisition Rationale</h2>If the acquisition goes through, it would bolster Sanofi’s footprint in ophthalmology, particularly in age-related macular degeneration, which affects the central part of the retina.At the same time, it could support Sanofi’s push into combination therapies, with Ocular’s treatments, such as Dextenza for ocular inflammation, potentially pairing well with existing drugs like Dupixent, given studies suggesting links between chronic skin conditions and eye disorders such as cataracts.<h2 class="st-heading-2">Sanofi’s Acquisition Spree</h2>Sanofi has been ramping up its strategy to add to its portfolio through key acquisitions over the last few months. In late December, Sanofi signed an agreement to acquire vaccine maker Dynavax Technologies Corp (DVAX) in a <a href="https://stocktwits.com/news-articles/markets/equity/why-did-dynavax-stock-surge-38-in-premarket-today/cLesA4mREHU">$2.2 billion deal</a> aimed at strengthening its adult immunization portfolio. The transaction will strengthen Sanofi’s global vaccines business by bringing in Dynavax’s approved adult hepatitis B vaccine, HEPLISAV-B, along with a differentiated shingles vaccine.In June, Sanofi agreed to <a href="https://stocktwits.com/news-articles/markets/equity/sanofi-to-buy-blueprint-medicines-for-up-to-9.5-billion/chkoCYnRbHc">acquire Blueprint</a> Medicines for about $9.1 billion to deepen its presence in the cure for rare immunological diseases. The acquisition added Ayvakit/Ayvakyit, the only approved treatment for systemic mastocytosis, along with pipeline assets including Elenestinib and BLU-808 to Sanofi’s portfolio.<h2 class="st-heading-2">How Did Retail React?</h2>Retail sentiment for OCUL on Stocktwits remained in the ‘extremely bullish’ zone over the past 24 hours, accompanied by ‘extremely high’ message volumes.<figure class="image"><img src="https://news.stocktwits-cdn.com/OCUL_jpg_9ede93e8cf.webp" alt="OCUL.jpg" width="928" height="100"><figcaption>OCUL's Sentiment Meter and Message Volumes at Premarket on Jan. 15, 2026 | Source: Stocktwits</figcaption></figure>One user sees upside in OCUL stock due to the offer.<stembedurl>https://stocktwits.com/scholar9/message/641880419</stembedurl>OCUL shares have gained around 34% over the past year.Read also: <a href="https://stocktwits.com/news-articles/equity/markets/nasdaq-sp500-futures-pause-nvda-tsm-msft-cvx-stocks-to-watch/cmU1L2fR47N">Nasdaq, S&amp;P 500 Futures Pause Ahead Of Major Bank Earnings, Jobless Claims: Why NVDA, TSM, CVX, MSFT, AMZN Are On Traders' Radar Today</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

A candlestick chart can be seen in a trading platform on a smartphone. Top U.S. firms announced record buybacks this year. (Photo by Silas Stein/picture alliance via Getty Images)

Why Did OCUL Stock Jump 13% In Pre-Market Today?

French pharmaceutical giant Sanofi is preparing an offer to acquire the American biopharmaceutical firm, according to a report by French publication La Lettre.

OCUL Stock Back On Retail Radar With Sanofi Takeover Speculation Resurfacing

Equity

Is Invesco Pharmaceuticals ETF (PJP) a Strong ETF Right Now?

<ul class="summary-bullets"><li>The trial had 24 patients, exceeding the original target of 20, and included a 4-week baseline.</li><li>In the Absence cohort, patients experienced a median 73.1% reduction in seizures.</li><li>The DEE cohort saw a median 63.3% decrease in major motor seizures.</li></ul>Shares of Bright Minds Biosciences Inc. (DRUG) rose over 51% on Tuesday morning, after the company announced promising topline results from its Phase 2 BREAKTHROUGH trial evaluating BMB-101.BMB-101 is a selective 5-HT2C biased agonist, in adults with drug-resistant Absence Seizures and Developmental and Encephalopathic Epilepsies (DEE). The study met its primary goals, showing strong reductions in seizure frequency while maintaining a favorable safety profile.<h2 class="st-heading-2">Trial And Participants</h2>The trial had 24 patients, exceeding the original target of 20, and included a 4-week baseline, 4-week titration, and maintenance period consisting of&nbsp;2 weeks for the Absence cohort and 4 weeks for the DEE cohort.&nbsp;Participants were heavily pretreated, with a median of 3 anti-seizure medications in the Absence cohort and 5 in the DEE cohort, having failed multiple prior therapies.&nbsp;On Stocktwits, retail sentiment around the&nbsp;<a href="https://stocktwits.com/symbol/DRUG">stock</a> jumped to ‘extremely bullish’ from ‘bearish’ territory. Message volume improved to ‘extremely high’ from ‘low’ levels in 24 hours.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2026_01_06_085410_png_a041b522e5.webp" alt="DRUG’s Sentiment Meter and Message Volume as of 09:35 a.m. ET on Jan. 6, 2026 | Source: Stocktwits" width="924" height="102"><figcaption>DRUG’s Sentiment Meter and Message Volume as of 09:35 a.m. ET on Jan. 6, 2026 | Source: Stocktwits</figcaption></figure><h2 class="st-heading-2">Seizure Reduction</h2>In the Absence cohort, patients experienced a median 73.1% reduction in seizures lasting more than or equal to three seconds and a 74.4% decrease in total seizure time over 24 hours.&nbsp;The DEE cohort, including patients with Lennox-Gastaut Syndrome (LGS), Dravet syndrome, and Rett syndrome, saw a median 63.3% decrease in major motor seizures. LGS patients achieved a 60.3% reduction, while other DEE participants experienced a 76.1% reduction.&nbsp;Beyond seizure control, BMB-101 increased REM sleep by 90%, from 56.2 to 106.7 minutes, without altering total sleep duration.DRUG stock has gained over 93% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-did-arwr-stock-surge-pre-market-today/cmxwuZ6R4TS">Why Did ARWR Stock Surge Over 15% Pre-Market Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

The Technician Reads Eeg Data While Subjecting The Boy To A Variety Of Visual And Respiratory Stimuli Stroboscopy.

Why Did DRUG Stock Rocket 51% Today?

The Phase 2 BREAKTHROUGH trial met its primary goals, showing strong reductions in seizure frequency while maintaining a favorable safety profile.

<ul class="summary-bullets"><li>The interim data show that ARO-INHBE, especially when combined with tirzepatide, doubled weight loss and tripled reductions in visceral fat.</li><li>In adults with obesity, a single 400 mg dose of ARO-INHBE reduced serum Activin E by a mean of 85%, reaching a maximum reduction of 94%.</li><li>ARO-ALK7 became the first RNAi therapy to silence an adipocyte gene in humans.</li></ul>Arrowhead Pharmaceuticals Inc. (ARWR) stock jumped over 15% in Tuesday’s premarket, after it released early data from its Phase 1/2a clinical trials of its RNA interference (RNAi) therapies, ARO-INHBE and ARO-ALK7, targeting obesity.&nbsp;The preliminary results suggest these investigational treatments may reduce body fat and improve metabolic health in patients, particularly those with type 2 diabetes.<h2 class="st-heading-2">Promising Fat Reduction</h2>The interim data show that ARO-INHBE, especially when combined with tirzepatide, a GLP-1/GIP receptor co-agonist, doubled weight loss and tripled reductions in visceral fat, total fat, and liver fat compared with tirzepatide alone.The findings mark the first human evidence that targeting the Activin E/ALK7 pathway could enhance weight loss beyond that achieved by existing incretin therapies. In adults with obesity, a single 400 mg dose of ARO-INHBE reduced serum Activin E by a mean of 85%, reaching a maximum reduction of 94%.On Stocktwits, retail sentiment around Arrowhead stock jumped to ‘bullish’ from ‘bearish’ territory. Message volume shifted to ‘high’ from ‘low’ levels in 24 hours.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2026_01_06_081204_png_73fc92d26b.webp" alt="ARWR’s Sentiment Meter and Message Volume as of 08:00 a.m. ET on Jan. 6, 2026 | Source: Stocktwits" width="932" height="105"><figcaption>ARWR’s Sentiment Meter and Message Volume as of 08:00 a.m. ET on Jan. 6, 2026 | Source: Stocktwits</figcaption></figure><h2 class="st-heading-2">Clinical Highlights</h2>ARO-INHBE monotherapy at week 16 led to a 9.9% reduction in visceral fat, a 38% drop in liver fat, and a 3.6% increase in lean muscle. Two doses at week 24 further improved visceral fat reduction to 15.6% after adjusting for placebo.&nbsp;Combined with tirzepatide, ARO-INHBE achieved roughly double the weight loss and triple the fat reduction compared to tirzepatide alone.ARO-ALK7 became the first RNAi therapy to silence an adipocyte gene in humans, reducing ALK7 mRNA in fat tissue by an average of 88% at the 200 mg dose, with a peak reduction of 94%. Early data also showed a 14.1% reduction in visceral fat after a single dose at week 8, adjusted for placebo.ARWR stock has gained over 227% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/ondas-stock-draws-bullish-retail-chatter-ahead-of-key-investor-event-trader-calls-it-potential-multibagger/cmxwMoyR4T0">Ondas Stock Draws Bullish Retail Chatter Ahead Of Key Investor Event – Trader Calls It ‘Potential Multibagger’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Arrowhead Pharmaceuticals logo is seen displayed on a smartphone screen.

Why Did ARWR Stock Surge Over 15% Pre-Market Today? 

The preliminary results from Phase 1/2a clinical trials of the company’s  RNA interference (RNAi) therapies suggest the treatments may reduce body fat and improve metabolic health in patients, particularly those with type 2 diabetes.

Should You Invest in the Invesco Pharmaceuticals ETF (PJP)?

Pharma's $370B Bet on America: The ETF Plays for 2026

Pharma ETFs like IHE are gaining traction as drugmakers pledge $370 billion to U.S. projects, fueling a new investment super-cycle heading into 2026.

Pharma ETFs to Gain From Landmark UK-US Zero-Tariff Deal

Pharma ETFs like IHE are poised to surge as the UK-US zero-tariff deal raises UK drug prices and strengthens major U.S. players' outlook. 

<ul class="summary-bullets"><li>As part of the agreement, the U.K. government will lift the threshold used by the NHS to determine if a drug is cost-effective by 25%.</li><li>It has also agreed to a reduction in the industry sales rebate on NHS drug prices to 15% in 2026 from the nearly 23% currently.</li></ul>The United States and the United Kingdom have reached an in-principle agreement on a zero-tariff deal on pharmaceuticals.According to the agreement’s details announced by the Office of the United States Trade Representative, the deal will result in zero tariffs on pharmaceutical products imported in the U.S. from the U.K. It will also lead to an increase in the U.K. government’s spending on the National Health Service (NHS).The agreement between the U.S. and U.K. on pharmaceutical pricing will remain in effect until the end of President Donald Trump’s term in 2029.In exchange, the U.K. government has agreed to a reduction in the industry sales rebate on NHS drug prices to 15% in 2026 from the nearly 23% currently, and remain at that level or below until 2029.<a href="https://stocktwits.com/symbol/AZN">AstraZeneca Plc.’s</a> (AZN) shares were flat in Monday’s opening trade. Retail sentiment around the company trended in the ‘bullish’ territory at the time of writing. AstraZeneca is the U.K.’s largest pharmaceutical company.<h2 class="st-heading-2">Increase In NHS Spending</h2>As part of the agreement, the U.K. government will also lift the threshold used by the NHS to determine if a drug is cost-effective by 25%.“Today’s agreement is a major win for American workers and our innovation economy. We are strengthening supply chains, creating high-quality jobs, and reinforcing America as the world’s premier hub for life-sciences investment,” said Secretary Howard Lutnick.<h2 class="st-heading-2">US-UK Trade Deal</h2>President Trump&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/trump-unveils-us-uk-trade-deal-with-boost-for-steel-agriculture-boeing/chifoL4RbkK">unveiled</a> the U.S.-U.K. trade deal in July, stating that it will open up billions of dollars in market access for exports from the United States. This also included a $10 billion aircraft sale involving Boeing Co. (BA).“With this deal, the U.K. joins the U.S. in affirming that reciprocity and fairness is an essential and vital principle of international trade,” President Trump said following the announcement in July.The deal eased restrictions on exports of beef, ethanol, chemicals, machinery, and other industrial products.&nbsp;<a href="https://stocktwits.com/symbol/AZN">AZN stock</a> is up 41% year-to-date and 37% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/michael-burry-tesla-ridiculously-over-valued-elon-musk/cLI7OPvREie">Michael Burry Takes Aim At Musk’s Tesla Again, Says TSLA Stock Is Still ‘Ridiculously Overvalued’: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

UK Prime Minister Sir Keir Starmer meets with U.S. President Donald Trump, during a bilateral meeting in the Oval Office at the White House

US, UK Reach In-Principle Agreement On Zero-Tariffs On Pharmaceuticals

The agreement between the U.S. and U.K. on pharmaceutical pricing will remain in effect until the end of President Donald Trump’s term in 2029.

Pharma ETFs in Spotlight Following Robust Q3 Earnings Results

Pharma ETFs like IHE and PPH are rallying as strong Q3 earnings across major pharmaceutical companies lift sector sentiment.

Does Trump's MFN Policy Put Pharma ETFs in the Crosshairs?

With Trump's MFN policy cutting U.S. drug prices, will Pharma ETFs such as IHE, heavily weighted toward Eli Lilly and Novo Nordisk, lose momentum?


Invesco Capital Management LLC - Invesco Pharmaceuticals ETF

Up 10% or more

0% to up 9%

Down 1% to 9%

Down 10% or more

The S&P 500 enters 2026 after a strong run. What kind of return do you expect this year?

How will the S&amp;P 500 perform in 2026?

PJP
Invesco Dynamic Pharmaceuticals ETF

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest PJP News

PJPInvesco Dynamic Pharmaceuticals ETF